Private equity fund managers expect to close more new deals in the coming year than they did during the past 12 months, according to the second annual PErspective study by BDO USA, LLP.   Almost half (49 per cent) of respondents expect to close three or more deals during the

Venture capital and growth equity firm Accel Partners is planning planning to open a New York City office. The firm currently manages over USD6bn globally and also has offices in Palo Alto, Bangalore, Beijing, London, New Delhi, and Shanghai. Accel Partners has made over 15 investments in companies in the

Private equity firm GTCR has entered into a partnership with David Minella to form Aligned Asset Managers (AAM), which will focus on building a multi-strategy asset management platform through substantial equity investments in firms across alternative and traditional asset classes. GTCR, the firm that pioneered the Leaders Strategy of partnering

Harold O Rosser a 20-plus year veteran of the private equity industry has formed Rosser Capital Partners (RCP) which will focus primarily on restaurant investments, in addition to consumer and multi-unit retail companies. "I believe now is an appropriate time in my career to establish an independent platform from which

Monomoy Capital Partners, a private equity firm that makes control equity investments in under-performing companies in the lower middle market, has held the final closing of its second restructuring fund, Monomoy Capital Partners II with USD400 million of Limited Partner commitments.   Monomoy’s Fund II exceeded the firm’s USD350 million

Lower middle-market buyout firm High Street Capital has completed the sale of Countryside Hospice Care, a wholly-owned portfolio company of High Street Capital III SBIC, to SolAmor Hospice, a subsidiary of Sun Healthcare Group. Countryside, which is based in Anniston, Alabama and provides in-home hospice services in 114 counties in

Holtzbrinck Ventures has closed its fourth Fund, HV Holtzbrinck Ventures Fund IV at EUR177m, raising capital from both Verlagsgruppe Georg von Holtzbrinck and funds managed by HarbourVest Partners, LLC. Holtzbrinck Ventures, which will now operate as a fully independent venture fund, will continue to execute its strategy of investing in

EyeSense AG, a venture capital-backed developer of novel ophthalmic self-diagnostic systems for glucose monitoring of diabetes patients, has entered into a strategic partnership with QIAGEN. Capitalising on QIAGEN’s ESE fluorescence-based optical technology and on Eyesense’s glucose sensing technology, the partners intend to develop a new optical measurement technology for blood